Cargando…

Hypoglycemia in Type 1 Diabetic Pregnancy: Role of preconception insulin aspart treatment in a randomized study

OBJECTIVE: A recent randomized trial compared prandial insulin aspart (IAsp) with human insulin in type 1 diabetic pregnancy. The aim of this exploratory analysis was to investigate the incidence of severe hypoglycemia during pregnancy and compare women enrolled preconception with women enrolled dur...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heller, Simon, Damm, Peter, Mersebach, Henriette, Skjøth, Trine Vang, Kaaja, Risto, Hod, Moshe, Durán-García, Santiago, McCance, David, Mathiesen, Elisabeth R.
Formato:	Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2010
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2827491/ https://www.ncbi.nlm.nih.gov/pubmed/20007944 http://dx.doi.org/10.2337/dc09-1605

Ejemplares similares

Poor pregnancy outcome in women with type 1 diabetes is predicted by elevated HbA(1c) and spikes of high glucose values in the third trimester
por: Damm, Peter, et al.
Publicado: (2014)

Maternal Efficacy and Safety Outcomes in a Randomized, Controlled Trial Comparing Insulin Detemir With NPH Insulin in 310 Pregnant Women With Type 1 Diabetes
por: Mathiesen, Elisabeth R., et al.
Publicado: (2012)

A randomized trial comparing perinatal outcomes using insulin detemir or neutral protamine Hagedorn in type 1 diabetes
por: Hod, Moshe, et al.
Publicado: (2014)

Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial
por: Niskanen, Leo, et al.
Publicado: (2012)

Preconception counselling resource for women with diabetes
por: Gough, Aisling, et al.
Publicado: (2015)

Efficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naïve Patients with Type 2 Diabetes: A Randomized Controlled Trial
por: Kumar, Ajay, et al.
Publicado: (2016)

Insulin Degludec/Insulin Aspart Administered Once Daily at Any Meal, With Insulin Aspart at Other Meals Versus a Standard Basal-Bolus Regimen in Patients With Type 1 Diabetes: A 26-week, phase 3, randomized, open-label, treat-to-target trial
por: Hirsch, Irl B., et al.
Publicado: (2012)

Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal–bolus treatment in people with Type 1 diabetes: 1–year results from a randomized clinical trial (BOOST (®) T1)
por: Hirsch, I. B., et al.
Publicado: (2016)

Risk of Major Congenital Malformations or Perinatal or Neonatal Death With Insulin Detemir Versus Other Basal Insulins in Pregnant Women With Preexisting Diabetes: The Real-World EVOLVE Study
por: Mathiesen, Elisabeth R., et al.
Publicado: (2021)

Low-Volume Insulin Degludec 200 Units/mL Once Daily Improves Glycemic Control Similarly to Insulin Glargine With a Low Risk of Hypoglycemia in Insulin-Naïve Patients With Type 2 Diabetes: A 26-week, randomized, controlled, multinational, treat-to-target trial: The BEGIN LOW VOLUME trial
por: Gough, Stephen C.L., et al.
Publicado: (2013)

Poor pregnancy outcome after octreotide treatment during pregnancy for familial hyperinsulinemic hypoglycemia: a case report
por: Skajaa, Gitte O, et al.
Publicado: (2014)

Efficacy and safety of once‐daily insulin degludec/insulin aspart compared with once‐daily insulin glargine in participants with Type 2 diabetes: a randomized, treat‐to‐target study
por: Kumar, S., et al.
Publicado: (2016)

Pregnancy outcomes in women with type 1 diabetes using insulin degludec
por: Ringholm, Lene, et al.
Publicado: (2022)

The Techniques: middleware developers' golden rules
por: Gavin McCance
Publicado: (2008)

Elderly Patients with Diabetes Experience a Lower Rate of Nocturnal Hypoglycaemia with Insulin Degludec than with Insulin Glargine: A Meta-Analysis of Phase IIIa Trials
por: Sorli, Christopher, et al.
Publicado: (2013)

Insulin Requirements in Type 1 Diabetic Pregnancy: Do twin pregnant women require twice as much insulin as singleton pregnant women?
por: Callesen, Nicoline F., et al.
Publicado: (2012)

Projected long‐term outcomes in patients with type 1 diabetes treated with fast‐acting insulin aspart vs conventional insulin aspart in the UK setting
por: Russell‐Jones, David, et al.
Publicado: (2017)

Clinical Pharmacology of Fast-Acting Insulin Aspart Versus Insulin Aspart Measured as Free or Total Insulin Aspart and the Relation to Anti-Insulin Aspart Antibody Levels in Subjects with Type 1 Diabetes Mellitus
por: Haahr, Hanne, et al.
Publicado: (2018)

Design and rationale of a large, international, prospective cohort study to evaluate the occurrence of malformations and perinatal/neonatal death using insulin detemir in pregnant women with diabetes in comparison with other long-acting insulins
por: Mathiesen, Elisabeth R., et al.
Publicado: (2017)

Endocrine Autoimmunity and Associated Conditions
por: McCance, David R
Publicado: (1999)

Membership Matters
por: McCance, David R.
Publicado: (1998)

The Role of the Developing Kidney in the Maintenance of Internal Stability
por: McCance, R. A.
Publicado: (1972)

DNA Cloning 3: Complex genomes: Edited by D.M. Glover and B.D. Hames. Oxford Science, Oxford. ISBN 0-19-963483-1; 0-19-963482-3. Price: £50 (hardback); £25 (paperback)
por: McCance, Dennis J.
Publicado: (1996)

Hypoglycemia in patient with type 2 diabetes treated with insulin: it can happen
por: Heller, Simon R, et al.
Publicado: (2020)

Cost-effectiveness of insulin degludec/insulin aspart versus biphasic insulin aspart in Chinese population with type 2 diabetes
por: Luo, Qiong, et al.
Publicado: (2022)

A New-Generation Ultra-Long-Acting Basal Insulin With a Bolus Boost Compared With Insulin Glargine in Insulin-Naïve People With Type 2 Diabetes: A randomized, controlled trial
por: Heise, Tim, et al.
Publicado: (2011)

IGF-Binding Protein 2 – Oncogene or Tumor Suppressor?
por: Pickard, Adam, et al.
Publicado: (2015)

CopenFast trial: Faster-acting insulin Fiasp versus insulin NovoRapid in the treatment of women with type 1 or type 2 diabetes during pregnancy and lactation - a randomised controlled trial
por: Nørgaard, Sidse Kjærhus, et al.
Publicado: (2021)

Hypoglycaemia is reduced with use of inhaled Technosphere(®) Insulin relative to insulin aspart in type 1 diabetes mellitus
por: Seaquist, E. R., et al.
Publicado: (2019)

Meta-analysis of insulin aspart versus regular human insulin used in a basal–bolus regimen for the treatment of diabetes mellitus
por: Heller, Simon, et al.
Publicado: (2013)

Insulin Pump Therapy With Automated Insulin Suspension in Response to Hypoglycemia: Reduction in nocturnal hypoglycemia in those at greatest risk
por: Choudhary, Pratik, et al.
Publicado: (2011)

Mealtime fast‐acting insulin aspart versus insulin aspart for controlling postprandial hyperglycaemia in people with insulin‐resistant Type 2 diabetes
por: Bowering, K., et al.
Publicado: (2018)

Faster‐acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart
por: Heise, T., et al.
Publicado: (2015)

Insulin allergy and resistance successfully treated by desensitisation with Aspart insulin
por: Matheu, Victor, et al.
Publicado: (2005)

The Alteration of Aspart Insulin Pharmacodynamics When Mixed With Detemir Insulin
por: Cengiz, Eda, et al.
Publicado: (2012)

Insulin Degludec Aspart: The First Co-formulation of Insulin Analogues
por: Kalra, Sanjay
Publicado: (2014)

Faster Insulin Aspart for Continuous Subcutaneous Insulin Infusion: Is It Worth It?
por: Rosinha, Patrícia, et al.
Publicado: (2022)

WLCG Input to Pisa workshop on Resilience-Explicit Computing in Grids
por: Shiers, J, et al.
Publicado: (2008)

Performance of Fast-Acting Aspart Insulin as Compared to Aspart Insulin in Insulin Pump for Managing Type 1 Diabetes Mellitus: A Meta-Analysis
por: Dutta, Deep, et al.
Publicado: (2023)

Hypoglycemia and Cardiovascular Risks
por: Frier, Brian M., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_rmsfn4odpm3v3e7ggldqighlmi